Precision at Scale: Optimizing Cell-Free DNA Manufacturing for Next-Generation mRNA Vaccines and Therapeutics
A Smarter Starting Material for Advanced Therapies
Future-Proofing Your CMC Strategy: Managing Critical Starting Material Changes
Discover how our synthetic DNA accelerates mRNA manufacturing
The Switch to Cell-Free DNA: Strategic and Regulatory Considerations for Advanced Therapies
A Smarter Starting Material for Advanced Therapies
opDNA: A Novel Synthetic DNA Starting Material for the Production of mRNA Therapies and Vaccines
Discover how our synthetic DNA accelerates mRNA manufacturing